rethinkTHC Search
Menu
Study breakdown

Combining THC and Opioids Did Not Improve Pain Relief for Knee Osteoarthritis

Clinical TrialStrong evidence
The takeaway

In a controlled trial of 21 adults with knee osteoarthritis, neither dronabinol (synthetic THC) alone nor combined with hydromorphone produced meaningful pain relief, and the combination impaired memory and increased nausea.

Pain medicine specialists, rheumatologists, cannabis-as-medicine researchers, patients considering cannabinoid-opioid combinations

What the researchers found

In a within-subject, double-blind trial, hydromorphone showed some analgesic effects on specific pain measures (pressure pain threshold, mechanical temporal summation) but neither drug reduced clinical pain severity or most experimentally induced pain measures. Critically, combining dronabinol and hydromorphone did not produce synergistic analgesia, contradicting preclinical data. The combination impaired working memory reaction time, produced higher subjective drug effects and "High" ratings, and caused more nausea than either drug alone.

Why it matters

This well-designed trial directly tests the popular hypothesis that combining cannabinoids with opioids could reduce pain more effectively while potentially lowering opioid doses. The negative result challenges this clinical strategy, at least for acute dosing in chronic pain populations.

The numbers in context

21 participants; dronabinol 10 mg; hydromorphone 2 mg; no significant clinical pain reduction for any condition; no synergistic effects; combination impaired working memory and increased nausea and "High" ratings; hydromorphone alone improved some experimental pain measures

How the study worked

Within-subject, double-blind, randomized, placebo-controlled trial. 21 adults (57% women, mean age 63.4) with knee osteoarthritis received four oral drug combinations across separate sessions: placebo, hydromorphone (2 mg), dronabinol (10 mg), and both combined. Assessed clinical and experimental pain, physical function, cognition, subjective effects, and adverse events at baseline and 60-240 minutes.

What this study cannot tell us

Small sample size (N=21). Single acute doses tested; chronic dosing might yield different results. Relatively low doses of both drugs. KOA represents one specific type of chronic pain. Within-subject design is a strength but may have learning effects across sessions.

How to read the evidence

Strong: well-designed double-blind, placebo-controlled crossover trial with comprehensive pain assessment battery, though small sample.

When this study was published

2025 publication

The bigger picture

The disconnect between promising preclinical combination studies and this negative clinical result highlights a common challenge in translating animal pain research to human chronic pain conditions. Knee osteoarthritis may involve pain mechanisms that are not responsive to acute opioid-cannabinoid combinations.

Questions still open

  • Would higher or chronic doses produce different results?
  • Are there chronic pain conditions where cannabinoid-opioid synergy does translate from animal to human data?

Read the original research

Evaluating the Acute Effects of the Cannabinoid Dronabinol and the Opioid Hydromorphone Alone and in Combination: A Double-Blind, Randomized, Placebo-Controlled Trial in Knee Osteoarthritis.

Anesthesiology

Citation

Hamilton, Katrina R; Mun, Chung Jung; Sadik, Eliot; Bergeria, Cecilia L; Huhn, Andrew S; Speed, Traci J; Vandrey, Ryan; Dunn, Kelly E; Campbell, Claudia M. (2025). Evaluating the Acute Effects of the Cannabinoid Dronabinol and the Opioid Hydromorphone Alone and in Combination: A Double-Blind, Randomized, Placebo-Controlled Trial in Knee Osteoarthritis.. Anesthesiology. https://doi.org/10.1097/ALN.0000000000005925

Explore the wider topic